TVRD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Clinical ValidationThe Phase 1 results provide early human evidence that TTI-109 reaches its intended biological target while improving tolerability versus TTI-101. That combination supports continued development and may strengthen the program’s prospects across multiple STAT3-driven diseases.
Oral Differentiated PlatformAn oral downstream STAT3 inhibitor could offer a differentiated approach versus parenteral biologics that typically block single upstream pathways. A mechanism spanning cellular and humoral disease drivers may support broader utility if clinical efficacy is demonstrated.
Low Current LeverageMinimal reported debt reduces fixed financing obligations and avoids a major source of balance-sheet pressure while the company advances its pipeline. This gives management more flexibility than a highly leveraged structure, although future funding needs remain important.
Bears Say
No Current RevenueThe disappearance of reported revenue leaves the company dependent on future clinical and commercial milestones rather than an operating income stream. Persistent deep losses also limit internal funding capacity and make financial performance highly dependent on pipeline execution.
Persistent Cash BurnOngoing cash outflows mean Tvardi must continue financing research and operations externally while its candidates remain in development. Even though burn improved from earlier periods, continued negative cash generation can constrain program timing and strategic flexibility.
Funding And Dilution RiskReliance on additional equity financing can increase the share count and dilute existing holders while funding clinical programs. The explicit dependence of planned studies on new capital also creates execution risk if financing capacity or market access becomes less favorable.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is CHF17.76M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 53 days.
How were Tvardi Therapeutics’s earnings last quarter?
Tvardi Therapeutics released its earnings results on Aug 14, 2026. The company reported -CHF0.565 earnings per share for the quarter, beating the consensus estimate of -CHF0.576 by CHF0.011.
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Tvardi Therapeutics have?
Currently, no data Available
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Tvardi Therapeutics reported an EPS of -CHF0.565 in its last earnings report, beating expectations of -CHF0.576. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in CH:TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
TVRD Stock 12 Month Forecast
Average Price Target
――
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―